Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection

References

• Lessa FC, Winston LG, McDonald LC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Jun 11;372(24):2369–2370.
   PubMedGoogle Scholar
• Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011 Apr;32(4):387–390.
   PubMed Web of Science ®Google Scholar
• Ma GK, Brensinger CM, Wu Q, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Inter Med. 2017 Aug 1;167(3):152–158.
   PubMed Web of Science ®Google Scholar
• Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? [Journal article research support, non-U.S. Gov’t review]. Clin Microbiol Infect. 2012 Dec;18(Suppl 6):21–27.
   PubMed Web of Science ®Google Scholar
• Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection [Review]. J Hosp Infect. 2008 December;70(4):298–304.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Polyzos KA, Patouni K, et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence [Journal article meta-analysis research support, non-U.S. Gov’t review systematic review]. Int J Antimicrob Agents. 2012 Jul;40(1):1–8.
   PubMed Web of Science ®Google Scholar
• Bauer MP, Notermans DW, Van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011 Jan 1;377(9759):63–73.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994 Jun 22–29;271(24):1913–1918.
   PubMed Web of Science ®Google Scholar
• Louie TJ, Byrne B, Emery J, et al. Differences of the Fecal Microflora with Clostridium difficile therapies. Clin Infect Dis. 2015 May 15;60(Suppl 2):S91–7.
   PubMed Web of Science ®Google Scholar
• Pepin J, Valiquette L, Gagnon S, et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol. 2007 Dec;102(12):2781–2788.
   PubMed Web of Science ®Google Scholar
• Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1985;80(11):867–868.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease [Clinical trial journal article randomized controlled trial research support, non-U.S. Gov’t]. Am J Gastroenterol. 2002 Jul;97(7):1769–1775.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013 Apr;1084:478–498. quiz 499.
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):987–994.
   PubMed Web of Science ®Google Scholar
• Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;3(3):CD004610–CD004610.
   PubMed Web of Science ®Google Scholar
• Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018 Apr;23(2):60–63.
   PubMedGoogle Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015 Nov;45(Pt A): 139–145.
   PubMed Web of Science ®Google Scholar
• Meehan AM, Khanna S, Pardi D. Outcomes in patients with recurrent Clostridium difficile infection treated with vancomycin taper. Gastroenterology. 2017;152(5 suppl 1):S348.
   Web of Science ®Google Scholar
• Gentry CA, Giancola SE, Thind S, et al. A propensity-matched analysis between standard versus tapered oral vancomycin courses for the management of recurrent Clostridium difficile Infection [Journal Article]. Open Forum Infect Dis. 2017;4(4):ofx235.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection [Comparative study journal article randomized controlled trial research support, non-U.S. Gov’t]. Aliment Pharmacol Ther. 2015 May;41(9):835–843.
   PubMed Web of Science ®Google Scholar
• Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial [Clinical trial, phase II Clinical TRIAL, phase III Comparative study journal article randomized controlled trial]. Clin Infect Dis. 2017 Feb 1;64(3):265–271.
   PubMed Web of Science ®Google Scholar
• Sirbu BD, Soriano MM, Manzo C, et al. Vancomycin taper and pulse regimen with careful follow-up for patients with recurrent Clostridium difficile infection. Clin Infect Dis. 2017 Oct 15;65(8):1396–1399.
   PubMed Web of Science ®Google Scholar
• Umemura T, Ota A, Mutoh Y, et al. Efficacy of prolonged tapered and pulsed vancomycin regimen on recurrent Clostridioides difficile infection in the Japanese setting: a case control study [Journal article]. J Pharm Health Care Sci. 2019;5:19.
   PubMed Web of Science ®Google Scholar
• Majors D, Ellis P. Risk factors for recurrent clostridium difficile infections and strategies to decrease readmissions in a community hospital. Hosp Pharm. 2015;50(11):1003–1010.
   PubMedGoogle Scholar
• Bouza E, Alcala L, Marin M, et al. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy [Journal article observational study]. Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1777–1786.
   PubMed Web of Science ®Google Scholar
• Murphy MM, Patatanian E, Gales MA. Extended duration vancomycin in recurrent Clostridium difficile infection: a systematic review [Journal Article Review]. Ther Adv Infect Dis. 2018 Nov;5(6):111–119.
   PubMed Web of Science ®Google Scholar